Answers are grounded in this paper and cite their sources.
Camizestrant, a next-generation oral SERD, shows promise in preclinical models of ER+ breast cancer alone and in combination with CDK4/6 and PI3K/AKT/mTOR inhibitors to address endocrine resistance, a current barrier to treatment.
No takes yet. Share an insight, caveat, or question.
Lawson et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: